Replies to post #39381 on Biotech Values

[rfj1862]

RPRX

Don't thank me until the fibroids results are in. Although in the long run uterine fibroids represents a signficantly smaller market than endometriosis (1.5M vs 5.5M patients, plus Proellex is more likely to be used chronically and long-term for endometriosis), uterine fibroids is the nearer-term opportunity for RPRX.

Regarding the CMO: this doesn't stop big pharma from taking a run at RPRX anyway. I've already spammed my friends and colleagues in industry :-)

Frankly, I don't want to wait for this to be a billion-dollar company, which it will be if they successfully execute on Proellex alone. I'd rather skip the risk and take $200M.